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Targeting the fibroblast growth factor receptor family in cancer 
 
 
Abstract 
Fibroblast growth factors (FGFs) regulate a plethora of biological functions, in both 
the embryonic and adult stages of development, binding their cognate receptors and 
thus activating a variety of downstream signalling pathways. Deregulation of the 
FGF/FGFR signalling axis, observed in multifarious tumour types including 
squamous non-small cell lung cancer, occurs through genomic FGFR alterations that 
drive ligand-independent receptor signalling or alterations that support ligand-
dependent activation. Mutations are not restricted to the tyrosine kinase domain and 
aberrations appear to be tumour type dependent. As well as its complementarity and 
synergy with VEGF of particular interest is the interplay between FGFR and EGFR 
and the ability of these pathways to offer a compensatory signalling escape 
mechanism when either is inhibited. Hence there exists a rationale for a combinatorial 
approach to inhibition of these dysregulated pathways to reverse drug resistance. To 
date, several multi-target tyrosine kinase inhibitors as well as FGFR specific tyrosine 
kinase inhibitors, monoclonal antibodies and FGF ligand traps have been developed. 
Promising preclinical data has resulted in several drugs entering clinical trials. This 
review explores aberrant FGFR and its potential as a therapeutic target in solid 
tumors. 
 
Introduction 
Deregulated receptor tyrosine kinases (RTKs) result in activated  signal transduction 
pathways, that are characteristic of and essential to malignancy [1]. One of the best-
studied examples, and a paradigm to the fibroblast growth factor receptor (FGFR) 
family, is epidermal growth factor receptor (EGFR), a receptor tyrosine kinase 
belonging to the ErbB family [2], which has been implicated as a driver oncogene in 
the development of a plethora of different tumour types. Although several first- and 
second-generation tyrosine kinase inhibitors (TKIs) successfully bind to and inhibit 
mutant EGFR signalling the emergence of a drug resistant phenotype is the inevitable 
endpoint either through acquired secondary resistance mutations or bypass signalling 
pathways. 
 
Human FGFRs are a family of four RTKs (FGFR1–4) which bind a diverse family of 
18 FGF ligands. The role of FGFR in development has been proven by gain-of-
function mutations that result in dwarfism in model organisms and in humans (D). 
Similar to EGFR, aberrant FGFR signalling has emerged as a key factor in the 
pathogenesis of multiple cancers. A study by Greenman et al. which screened the 
coding exons of 518 protein kinase genes from 210 different human cancers 
demonstrated that the components of the FGF signalling pathway contained more 
non-synonymous mutations than all of the other kinases [3].  
Activated FGFR signalling is also a key driver of resistance to several targeted 
therapies. It was previously shown to be synergistic with VEGF and involved in 
resistance to anti-VEGF inhibition [4]. However, more recently, an intricate 
relationship between the EGFR and FGFR families has also emerged with activated 
FGFR1 identified as a bypass escape mechanism to the EGFR tyrosine kinase 
inhibitor afatinib [5], while comparably, EGFR activation has been identified as a 
mechanism of resistance in FGFR3-mutant bladder cancers [6]. The FGFR inhibitor 
PD-173074 was shown to rescue fibroblast induced lapatinib resistance in esophageal 
squamous cell lines [7]. Hence, dual targeting of the EGFR and FGFR pathways may 
be a more effective therapeutic strategy, as discussed subsequently in this review.  
Targeting FGFR has shown potential in previously difficult to treat tumour types 
including squamous non-small cell lung cancer (NSCLC) [8, A]. Herein we discuss 
the FGFR family and how deregulation of the FGFR signal transduction cascade 
contributes to cancer development, as well as the multiple targeted therapies in 
preclinical and clinical development.  
 
 
FGFs / FGFRs 
FGFs are secreted protein ligands that act in a paracrine or endocrine fashion to carry 
out their pleiotropic functions in development, tissue homeostasis and metabolism [9]. 
The first FGFs, namely acidic FGF and basic FGF, were discovered in the 1970’s as 
mitogens derived from bovine brain tissue [10]. Since this time many more members 
of the FGF family have been identified in a variety of different organisms, 
encompassing both vertebrates and invertebrates, however, FGF-like sequences have 
not been identified in unicellular organisms [11]. The mammalian FGF family 
comprises eighteen highly conserved ligands (FGF1-10, FGF16-23), which are 
grouped into five paracrine-acting subfamilies and one endocrine-acting subfamily [9] 
and 4 FGF homologous factors (FGF11-14), which have high sequence identity to 
FGF ligands but do not activate FGF receptors [12]. There is no human FGF15; rather 
murine FGF15 is orthologous to human FGF19 [12]. 
 
FGFs are known to play a crucial role in the regulation of a plethora of developmental 
processes, in both the embryonic and adult stages of life. During embryonic 
development FGFs are involved in the regulation of cellular proliferation, 
differentiation and migration, while in the adult organism FGFs play a part in many 
physiological roles. They are vital in the management of tissue repair; wound healing 
and tumour angiogenesis [12]. As such, it is crucial that FGF activity is tightly 
regulated in order to maintain homeostatic cellular proliferation. 
 
FGFRs are the receptors to which FGF ligands bind. The human FGFR family 
comprises of four members, FGFR1-4. FGFRs are transmembrane tyrosine kinases 
belonging to the immunoglobulin (Ig) superfamily. Similar to most other receptor 
tyrosine kinases, FGFRs are single pass transmembrane proteins consisting of an 
extracellular ligand binding domain, a hydrophobic transmembrane domain and an 
intracellular tyrosine kinase domain [13]. The extracellular region is composed of 
three Ig like domains, labelled D1-D3, with a stretch of seven or eight acidic, serine 
rich residues located between D1 and D2. This stretch is referred to as the acid box. It 
is thought that the first Ig-like domain, D1, plays a role in receptor auto inhibition, 
while the second and third domains comprise the ligand-binding site [14]. In FGFR1-
3 ligand-binding specificity is determined by alternative splicing of the third domain 
[15]. The N-terminal portion of D3 is encoded by a conserved exon (IIIa) while the C-
terminal tail is encoded by one of two mutually exclusive exons, labelled IIIb and IIIc 
respectively. In general, this alternative splicing is tissue specific. The IIIb isoform is 
primarily expressed in epithelial tissue while the IIIc isoform is expressed in 
mesenchymal tissue. Interestingly, the ligands for epithelial receptors are commonly 
expressed in mesenchymal tissue and vice versa, thus allowing for paracrine 
signalling between neighbouring tissues [16]. Alternative splicing does not occur in 
FGFR4. Rather FGFR4 is expressed as a lone isoform that is analogous to the 
FGFR2-IIIc isoform [17].  
 
A fifth member of the FGFR family, fibroblast growth factor receptor like 1 
(FGFRL1), was recently discovered. Analogous to the classical FGFRs, FGFRL1 
possesses three extracellular Ig-like domains. However it lacks a tyrosine kinase 
domain and instead contains a short intracellular tail with a histidine rich motif [18]. 
FGFRL1 is thought to negatively regulate signalling, inhibiting cellular proliferation 
and promoting differentiation. Trueb et al. investigated this idea and demonstrated 
that MG63 osteosarcoma cells transfected with FGFRL1 expression constructs 
proliferate at a much slower rate than control cells treated with antisense constructs 
[19].  
 
In addition to binding FGFRs, FGFs also have a strong affinity for the 
glycosaminoglycan side-chains of cell surface proteoglycans [16], in particular 
heparan sulphate proteoglycans (HSPGs). Secreted FGFs are sequestered on the 
surface of the secretory cell or nearby cells, consistent with their role as primarily 
short range signalling molecules. FGF-HSPG interactions are extremely important in 
FGF function as these interactions protect the ligand from thermal degradation and 
proteolysis [20] and help to stabilize the FGF-FGFR ternary complex. Thus with the 
help of HSPGs, FGFs exert their cellular function by binding to and consequently 
activating a family of receptor tyrosine kinases. 
 
 
Signalling 
The binding of FGFRs to their respective FGF ligands is the primary step in the 
initiation of the FGFR signalling pathway. This binding event induces receptor 
dimerization and thus a change in receptor conformation that allows for 
transphosphorylation of the tyrosine kinase domains and the intracellular tail. This in 
turn leads to the dissociation of a network of hydrogen bonds, which act as a 
molecular brake by preserving the kinase in an auto-inhibited state [21].  
 
Phosphorylated tyrosine sites on the receptor act as docking sites for various adaptor 
proteins that contain Src homology 2 domains (SH2) or phosphotyrosine binding 
domains (PTB). These adaptor proteins are then phosphorylated directly by FGFR 
[22]. The binding of the adaptor proteins to the receptor stimulates the activation of 
four downstream signalling pathways; Ras-Raf-MAPK, PI3K-AKT, Stat and PLCγ 
[17].  
 
One of the many adaptor proteins that facilitate signal transduction via FGFRs is 
FGFR substrate 2 (FRS2), of which there are two types, FRS2α and FRS2β. These 
key adaptor proteins bind to the juxtamembrane region of the receptor via their PTB 
domains. Upon binding, FRS2 proteins are phosphorylated by the FGFR, thus 
allowing for the recruitment of additional adaptor proteins; son of sevenless (SOS) 
and growth factor receptor-bound 2 (Grb2) resulting in the activation of downstream 
Ras/MAPK signalling pathway [23]. FRS2 also plays a role in the PI3K-AKT 
pathway through the docking protein Gab1, which binds to the SH3 domain of Grb2 
[22]. This binding event enables phosphorylation of Gab1, which is followed by 
recruitment of several signalling proteins including PI3K. The recruitment of PI3K by 
Gab1 causes activation of the Akt dependent anti-apoptotic pathway. 
 
Phospholipase Cγ (PLCγ) is another important signalling protein involved in FGF 
biology. PLCγ binds via its SH2 domain to an auto-phosphorylated site in the C-
terminal tail of the activated receptor, resulting in phosphorylation and activation of 
PLCγ [22]. Consequently PLCγ hydrolyses phosphatidylinositol 4,5-bisphosphate 
(PIP2) to the second messengers’ diacylglycerol (DAG) and inositol 1,4,5-
triphosphate (IP3), triggering the release of calcium and activating protein kinase C 
[26]. 
 
 Figure 1: Diagrammatic representation of the various signalling pathways that may be 
activated upon ligand binding and receptor dimerization. Note; PLC – Phospholipase C, 
STAT – Signal Transducers and Activators of Transcription, PI3K – Phosphoinositide 3-
kinase, Grb2 – Growth Factor Receptor-bound Protein 2. 
 
 
Deregulation of FGF-FGFR signalling in cancer 
Deregulated FGF/FGFR activity has been reported in a plethora of different cancer 
types, including solid tumours and haematological malignancies. Aberrant 
FGF/FGFR signalling may be achieved by several different ligand-independent 
mechanisms; these include mutations, chromosomal translocations or amplifications 
of the genes encoding FGFRs, which may give rise to receptor overexpression and 
thus increased receptor signalling. Alternatively impaired termination of FGF/FGFR 
signalling may result in increased levels of receptor on the cell surface and 
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consequently may contribute to tumorigenesis. Moreover, ligand-dependent signalling 
has also been shown to play a role in the development of some cancers, via autocrine 
or paracrine production of ligand. The aforementioned methods by which aberrant 
signalling may be achieved will be discussed in greater detail, with regard to various 
cancer types in the following sections. 
 
Gene Abberation Cancer Type 
FGFR1 Mutation 
Amplification 
 
 
Translocation 
Melanoma (rare) 
Lung cancer (10-20% SQC & 3% ADENO) Breast cancer 
(10%), ovarian cancer (~5%), bladder cancer (3%) and 
rhabdomyosarcoma (3%) 
Lung Cancer SQC (0.3-0.6%) 
FGFR2 Mutation 
 
Amplification 
Germline SNP 
Translocation 
Lung Cancer SQC (3%), Endometrial cancer (10-16%) and 
gastric cancer (rare) 
Gastric cancer (4-10%) and breast cancer (~1%) 
Second intron SNP: increased incidence of breast cancer 
Lung Cancer SQC (0.3%) 
FGFR3 Mutation 
 
 
 
Amplification 
Translocation 
Lung Cancer SQC (3%), Bladder cancer (50–60% non-muscle 
invasive type, 10–15% invasive type), cervical cancer (5%), 
myeloma (5% translocated cases), prostate (3%) and 
spermatocytic seminoma (7%) 
Bladder (NR), salivary adenoid cystic cancers (NR) 
Lung Cancer SQC (1-3.5%), Lung Cancer Adeno (0.5%) 
FGFR4 Mutation 
Germline SNP 
Rhabdomyosarcoma 
Coding SNP: poor prognosis breast, colon and lung 
adenocarcinoma 
FGF1 Amplification Ovarian (NR) 
 
Table 1.0 Summary of genetic aberrations within the FGF/FGFR axis in different 
solid tumors. 
 
 
FGFR Mutations 
Germline gain-of-function mutations in FGFRs have been reported in a variety of 
human skeletal dysplasia’s as well as in numerous human carcinomas. Mutations may 
occur in almost any part of the receptor [24]. Most mutations result in more active 
forms of the receptor, via enhanced ligand binding due to mutation of the extracellular 
domain, increased or constitutive receptor activation as a result of mutations in the 
ligand-binding domain and tyrosine kinase domain [25]. Other mutations have been 
shown to result in impaired degradation of the receptor and prolonged signalling, as 
discussed below. 
 
Endometrial cancer is the most common gynaecological malignancy in the Western 
world, with approximately 50,000 women diagnosed per annum in the US. alone. It 
has been shown that FGFR2 mutations are observed in 10-16% of endometrial 
carcinomas [26]. The majority of somatic mutations identified were identical to 
germline FGFR mutations associated with congenital craniofacial developmental 
disorders such as Apert Syndrome and Crouzon Syndrome [27]. 11 different FGFR 
mutations have been identified in endometrial cancer, with the S252W mutation the 
most frequently occurring. This mutation is known to occur in the ligand-binding 
region between D2 and D3. In vitro studies have shown that the S252W mutation 
increases the binding affinity of the receptor for multiple FGFs as well as disrupting 
the epithelial-mesenchymal ligand binding specificities attributed to alternatively 
spliced isoforms [28]. Thus the S252W mutation allows epithelial FGFR2b to bind 
epithelial ligands and mesenchymally expressed FGFR2c to bind mesenchymally 
expressed ligands, hence permitting ligand-dependent autocrine signalling. Dutt et al. 
have investigated knockdown of mutant FGFR2 expression using shRNA and 
inhibition of FGFR kinase activity [29]. These experiments demonstrated that 
knockdown of mutant FGFR2 resulted in inhibition of transformation and survival of 
endometrial cell lines expressing mutant FGFR2, while those expressing wild type 
FGFR2 were unaffected. Furthermore, treatment of mutant FGFR2 endometrial cell 
lines with the FGFR inhibitor PD173074 also resulted in a reduction of cell survival, 
indicating the potential for the development of targeted therapies in the future. It is 
worth mentioning that unlike translocations and amplifications, no association has 
been made between FGFR2 mutation and prognosis in endometrioid cases [30].  
 
Urothelial cell carcinoma (UCC) is the most common form of bladder cancer, 
accounting for approximately 90% of all bladder cancer cases [31]. UCC progresses 
via two molecular pathways, FGFR3 mutation or p53 mutation [32]. Cappallen et al. 
were the first to identify FGFR3 as being mutated in bladder cancers [33]. FGFR3 
mutations are the most frequent somatic mutations in UCC, occurring in about 70% of 
low-grade, non-invasive (pTa) tumours, which account for 75% of all UCC. The other 
pathway is characterized by high-grade, invasive tumours harbouring frequent 
mutations in the p53 tumour suppressor gene [32]. Mutations in FGFR3 and p53 have 
yet to be discovered concomitantly and are thought to be mutually exclusive. Almost 
all somatic mutations identified in bladder tumours are identical to specific germline 
FGFR mutations associated with thanatophoric dysplasia and order congenital 
craniosynostosis syndromes [34].  In a study by van Rhijn et al. it was shown that the 
S249C mutation in the extracellular domain is the most frequently occurring 
mutation, present in 30/34 mutated tumours tested [35]. This mutation results in the 
addition of a cysteine residue, leading to the formation of an intra-molecular 
disulphide bridge and hence constitutive dimerization and receptor activation. 
Interestingly, mutations were only observed in pTa tumours, no mutations were found 
in pT1 and higher staged tumours. Furthermore, FGFR3 mutations only occurred in 
grade 1 or grade 2 tumours, suggesting that FGFR3 mutations are linked with a 
favourable disease course in which lower staged tumours prevail [35]. van Rhijn et al. 
went on to investigate FGFR3 mutation in UCC and its recurrence rate. They found 
that FGFR3 mutated tumours are less likely to lead to recurrences as these tumours 
shed cells with a lower frequency than tumours that carry wild type FGFR3 [35]. 
However, these findings contradict numerous other studies, which suggest that 
FGFR3 mutation confers an increased risk of tumour recurrence [36]. Approximately 
70% of non-invasive tumours result in reoccurrence, but only 15-20% make the 
transition to invasive tumours. Monitoring of recurrence by cystoscopy is an 
expensive and uncomfortable procedure for patients. Recent studies suggest a role for 
mutated FGFR3 as a useful biomarker for tumour recurrence through detection of 
FGFR3 mutations in urine from patients with FGFR3 mutations in their primary 
tumour [37].  
 
In lung tumours somatic FGFR mutations occur at the same positions to germline 
FGFR2 and FGFR3 mutations and may play a role in lung cancer development. In a 
whole-genome sequencing study of 88 lung tumours FGFR mutations were detected 
in 10% of tumours (3). The mutation rate in FGFR2 was 3.4% and demonstrated an 
excess of non-synonymous mutations indicating a role as an oncogenic driver.  
Another study evaluating FGFR2 and FGFR3 mutations in 178 lung squamous cell 
carcinomas identified 5 (W290C, T787K, S320C, K660N, E471Q) FGFR2 and 6 
(S249C (x2), S435C, S249C, S248C, K717M) FGFR3 mutations as well as an 
FGFR2 K660N mutation in a separate sample. In samples containing mutations the 
IIIb isoform of each protein was overexpressed compared with the IIIc isoforms. 
FGFR mutations co-occurred with mutations inTP53 in 8 out of 10 cases and PIK3CA 
in 3 out of 10 cases (I). In-vitro and xenograft model data demonstrated that kinase 
domain mutations ns K660E and K660N in FGFR2 as well as ECD mutations W290C 
and S320C in FGFR2 and R248C and S249C in FGFR3 significantly increased 
colony formation compared with wtFGFR2 or FGFR3. In contrast FGFR2 mutations 
E471Q and T787K and FGFR3 mutations S435C and K717M did not form colonies 
greater than WT (I). Non-synonymous FGFR4 mutations (P672T and E681K) have 
been reported in current smokers with lung adenocarcinoma (J, K). 
 
 
 
Chromosomal Translocations 
Intragenic chromosomal translocations have been shown to elicit potent oncogenic 
activity through the expression of fusion proteins, in which the N terminus of a 
transcription factor is fused to a tyrosine kinase domain of the receptor. This results in 
the kinase domain of the receptor being permanently dimerized in the absence of 
ligand and thus constitutively activated. Unlike wild type receptors, fusion proteins 
are expressed in the cytosol and so they can evade normal receptor degradation 
processes, thus enabling them to drive proliferation of cancer cells [38]. 
Whilehaematological malignancies show the greatest incidence of FGFR 
chromosomal rearrangements, FGFR1/3 fusions occur in approximately 1% of 
NSCLC or 2-3.5% of lung cancer patients with squamous cell carcinoma . .  
 
8p11 myeloproliferative syndrome (EMS) is a rare, aggressive cancer, which has been 
associated with chromosomal translocations involving the FGFR1 gene on 
chromosome 8p11-12 [39]. The t(8;13)(p11;q12) is the most common translocation 
identified in EMS. In this translocation, ZNF198 gene on chromosome 13 and FGFR1 
gene on chromosome 8 are disrupted and recombined to create a novel ZNF198-
FGFR1 fusion protein [40].  Furthermore, it was found using FISH analysis by Reiter 
et al. that the t(8;13) is not simply a reciprocal translocation but also involves 
inversion of the ZNF198 containing 13q11-12 region [41], perhaps explaining why 
t(8;13) translocations are so rare. At least 10 other fusion partners have been 
identified for FGFR1 to date. Numerous therapeutic programs have been used in the 
treatment of EMS, however the prognosis of EMS patients is poor. Few targeted 
therapies have been identified, including tyrosine kinase inhibitors [42] and 
interferons [43] but much more research is necessary to improve treatment plans for 
EMS patients.  
 
In approximately 15% of multiple myeloma (MM) cases a karyotypically silent 
t(4;14) translocation is observed, linking FGFR3 at 4p16.3 to the immunoglobulin 
heavy chain (IgH) locus at 14q32.3 [44]. This chromosomal translocation brings 
FGFR3 under the influence of a strong IgH switch region causing the overexpression 
of FGFR3 and contributing to the generation of an FGFR3 protein that is active in the 
absence of ligand. It was subsequently reported that another gene, MMSET was also 
affected by the t(4;14) translocation [45]. Overexpression of MMSET occurs in all 
t(4;14) cases, while FGFR3 overexpression occurs in ~70% of patients [46]. 
Furthermore, patients with t(4;14) translocation are the worst prognostic multiple 
myeloma subgroup, demonstrating a shorter period of remission [47], more 
aggressive relapse [48] and median survival of 3-4 years. This is irrespective of 
FGFR3 expression [49], suggesting MMSET may be the primary oncogene in t(4;14) 
translocation. 
 
NSCLC patients with FGFR fusions are more likely to be smokers, with larger more 
poorly differentiated tumours. In a study by Wu et al. 3 different types of FGFR 
fusions were identified (BAG4-FGFR1, FGFR2-KIAA1967, FGFR3-TACC3) 
showing sensitivity to FGFR inhibitors PD173074 and pazopanib (L). FGFR3-
TACC3 fusion transcripts were also detected in 0.5% lung cancer patients with 
adenocarcinoma and predominantly never/light smokers (M). 
 
 
FGFR overexpression and amplification 
The overexpression of FGFRs has been identified in numerous human cancers 
including; breast, prostate, lung, gastric, brain and head and neck. When 
overexpressed, individual FGFRs may interact with and phosphorylate one another in 
a ligand independent manner, culminating in aberrant signalling. 
 
A variety of FGFR abnormalities have been identified in breast cancer. There are 
three principal molecular subtypes of breast cancer that may be further classified 
accordingly. These are: luminal, which is oestrogen receptor (ER)/progesterone 
receptor (PR) positive, HER2, which is ER/PR negative and basal, which is 
ER/PR/HER2 negative [31]. Amplification of the 8p11-12 region, upon which 
FGFR1 is located, occurs in approximately 10-15% of all human breast cancers [50] 
and 16-27% of luminal type B breast cancers [51], resulting in FGFR1 amplification 
and overexpression. Moreover, FGFR1 amplification is more frequently observed in 
invasive breast cancer than in ductal in situ carcinoma. These amplifications are 
commonly found in the invasive components of the tumour, thus suggesting that 
FGFR1 may drive the transition from in situ to invasive disease [52]. The structure of 
the 8p11-12 amplicon has been determined using high-resolution comparative 
genome hybridisation analysis and has been shown to comprise of four separate cores, 
each of which may be independently amplified [53]. However, FGFR1 is not always 
overexpressed when amplified, as such its role as the driver mutation is debated. The 
prognostic significance of FGFR1 amplification and subsequent correlation of FGFR1 
overexpression to survival has been investigated [54]. It was shown that FGFR1 
amplification is an independent prognostic factor for disease free survival and overall 
survival in ER positive tumours only. Furthermore, it was demonstrated by Turner et 
al. [51] that patients with FGFR1 amplified tumours are more likely to show 
resistance to endocrine therapies, as a result of enhanced ligand-dependant signalling.  
 
FGFR2 amplification has been implicated in a small subset of breast cancers, 
occurring in approximately 4% of triple negative cancers [55]. FGFR2 amplification 
often results in FGFR2 overexpression accompanied by truncation of the most C-
terminally coding exon [56]. This deletion gives rise to the expression of a C-
terminally truncated receptor variant, resulting in impaired receptor internalisation, 
thus preventing signal attenuation and promoting constitutive receptor activation. 
Inhibition of FGFR2 signalling using the FGFR specific inhibitor PD173074 induced 
apoptosis, confirming the role of FGFR2 in these cancers [55]. These data indicate 
that FGFR amplification and overexpression are integral in the development of some 
breast cancers and represent possible future therapeutic targets. 
 
FGFR1 and FGFR4 are frequently overexpressed in human prostate cancer [57, 58]. It 
is thought that FGFR1 amplification acts to induce tumorigenesis by disrupting 
normal paracrine signalling between epithelial and mesenchymal cells in the prostate 
[59]. Acevedo et al. investigated this theory using prostate specific, genetically 
engineered murine (GEM) models. An inducible FGFR1 (iFGFR1) genetic construct 
(termed JOCK1), which juxtaposes CID and kinase 1, was directed at prostate 
epithelial cells, which, upon activation stimulated epithelial-mesenchymal transition 
and the development of prostate adenocarcinoma in 100% of mice. Furthermore, the 
effects of JOCK1 inhibition were tested at various stages during disease progression. 
Interestingly, inhibition of JOCK1 at an early stage led to complete regression of 
disease within 8 months, while late stage inhibition significantly reduced progression 
and proliferation but complete regression was not observed. These results indicate 
that there is a “susceptibility window” during which the targeting of inhibitors at 
FGFRs is most effective. 
 
Recent studies using FISH analysis have shown that FGFR1 is frequently amplified in 
NSCLC [60]. More specifically, approximately 10-20% of squamous cell carcinomas 
(SCC) and approximately 3% of adenocarcinomas show FGFR1 amplification. 
FGFR1 amplified tumours frequently harbour a mutation in p53 [61], thus 
contributing to oncogenesis. The prognostic significance of FGFR1 amplification has 
been investigated in several studies [62, 63], suggesting that patients with FGFR1 
amplified tumours show a decreased overall survival compared to patients whose 
tumours do not show FGFR1 amplification. However, results obtained from a single 
study by Heist et al. suggest that FGFR1 amplification makes no significant 
difference in the overall survival of patients [61]. The inhibition of FGFR1 was 
explored by Weiss et al. using PD173074, an FGFR inhibitor [62]. They showed that 
FGFR1 amplification led to FGFR1 dependency, which when inhibited, resulted in 
the induction of apoptosis. Hence, FGFR1 amplification represents a possible area for 
targeted therapy in the future [8]. A recent study by Cheng CL et al quantified FGFR1 
and FGFR2 expression in 714 triple-negative breast cancer tumors and identfied 
FGFR1 expression as an independent prognostic factor [64].   Patients negative for 
FGFR1 showed improved overall survival (OS) while those with a H-score >100 had 
the worst OS [64]. 
 
FGFR2 amplification occurs in approximately 4-10% of gastric cancers [65, 66], 
resulting in a highly overexpressed and constitutively activated receptor.  FGFR2 
amplified gastric tumours are associated with an aggressive diffuse type cancer and an 
overall poor prognosis [67, 68]. FGFR2 amplifications are mutually exclusive with 
other receptor tyrosine kinase amplifications such as ERBB2, MET and EGFR, 
suggesting that they may activate the same downstream signalling pathway in gastric 
cancer [66]. Kitsberg et al. investigated the role of FGFR2 in gastric cancer using 
transgenic murine models expressing the FGFR2 specific ligand, FGF7 [69]. They 
demonstrated that mice carrying this transgene proceeded to develop prostate 
hyperplasia in male models and mammary adenocarcinoma in females. Despite the 
above findings, the role of FGFR2 in tumorigenesis is somewhat debated, as it 
remains unclear whether or not FGFR2 amplification at 10q26 is the driver mutation 
in gastric carcinogenesis. It was shown by Kunii et al. that inhibition of FGFR2 using 
the FGFR specific inhibitor, PD1730174, resulted in cessation of cellular proliferation 
and induction of apoptosis in FGFR2-amplified cell lines [70]. These results indicate 
that the FGFR2 kinase is the driver of proliferation in FGFR2-amplified cell lines. 
Interestingly, elevated phosphotyrosine levels in EGFR, ERBB2 and Her2 were 
observed in FGFR2-amplified cell lines. This elevated phosphorylation was shown to 
be resistant to EGFR specific inhibitors, gefitinib and erlotinib, however the use of 
FGFR specific small molecule inhibitors resulted in the nullification of elevated 
phosphotyrosine, suggesting EGFR family members to be downstream targets of 
FGFR2 signalling in FGFR2-amplified cell lines [70]. In some gastric cancer cell 
lines, FGFR2 amplification is accompanied by truncation of the most C-terminal 
coding exon, as similarly described in FGFR2 amplified breast cancers [56].  
 
 
Autocrine-Paracrine Signalling 
Ligand-dependant signalling has also been shown to play a key role in the 
development of various cancers, by way of autocrine production of ligand in cancer 
cells or paracrine production of ligand by neighbouring stromal cells or in response to 
cancer cells. The earliest evidence linking FGF signalling to mammary oncogenesis 
came from studies of mouse mammary tumour virus (MMTV) [17], a maternally 
transmitted infection of neonatal mice. MMTV acts as an insertional mutagen, 
integrating into and disturbing the host genome [16]. Three members of the FGF 
family (FGF3, FGF4 and FGF5) have been described as activated oncogenes for 
MMTV. 
 
FGF autocrine signalling has been implicated in a multitude of different cancers 
including melanoma, pancreatic, and breast cancer. Elevated expression of FGFR1 
and its high-affinity ligand FGF2 has been identified in both primary and metastatic 
human melanomas [71].  In vitro studies have demonstrated that both FGFR1 and 
FGF2 are essential in sustaining malignant melanoma growth. Antisense-mediated 
inhibition of either FGFR1 or FGF2 resulted in inhibition of tumour cell proliferation 
and signs characteristic of differentiation [72, 73], suggesting that an FGFR1-FGF2 
autocrine loop may play a role in the development of malignant melanomas. 
 
Various in vitro studies have demonstrated that FGFs have a central role in pancreatic 
carcinogenesis via intracrine, autocrine and paracrine pathways. FGF1, 2, 5 and 7 are 
frequently overexpressed in pancreatic cancers [74-76]. The overexpression of FGF1 
and 2, which is associated with poor prognosis, is localized primarily in the cancer 
cells themselves. FGF2 isoforms are not readily secreted but rather are found in the 
nucleus, cytosol and on the cell surface, suggesting FGF2 growth stimulation occurs 
via intracrine signalling [77]. In contrast to this, FGF5 is located in adjacent stromal 
fibroblasts and islet cells while FGF7 overexpression is concentrated in surrounding 
acinar and ductal cells [77]. Potential for autocrine and paracrine signalling is 
apparent in FGF5 in particular, which contains a hydrophobic N-terminal sequence 
for secretion, typical for efficiently secreted proteins [75]. 
 
Strong evidence implicating FGF paracrine signalling and oncogenic transformation 
comes from studies of prostate adenocarcinomas. As described earlier, it is thought 
that FGFR1 amplification acts to induce tumorigenesis by disrupting normal paracrine 
signalling between epithelial and mesenchymal cells in the prostate [59]. Memarzadeh 
et al. demonstrated that enhanced expression of FGF10, which is distinctly expressed 
by mesenchymal cells, could induce the formation of multifocal prostate 
adenocarcinoma accompanied with increased androgen receptor expression [78]. 
Furthermore, it was shown that paracrine signalling of FGF10 led to androgen 
independent survival and proliferation of cancer cells. Paracrine FGF10 signalling 
synergises with activated AKT, leading to high-grade carcinomas, illustrating the 
importance of epithelial-mesenchymal cooperation in malignant transformations.  
 
In addition to autocrine and paracrine signalling, FGFs have also been shown to 
signal in an endocrine manner. Such hormonal FGFs, such as FGF19, FGF21 and 
FGF23 travel via the bloodstream in order to exert their physiologic effects. The role 
of FGF19 in invasive ductal carcinoma of the breast has been investigated by 
Buhmeida et al [79], who determined the level of FGF19 expression in 193 breast 
tumour samples by immunohistochemistry and subsequently evaluated samples 
semiquantitatively, dividing them into two distinct groups based on the intensity of 
FGF19 expression. Low FGF19 expression was observed in approximately 40% of 
samples, compared with high FGF19 expression in approxiamtely 60% of samples 
tested. Interestingly, high FGF19 expression occurred more frequently in younger 
patients. Furthermore, it was shown that there is significant correlation between 
FGF19 expression and 5 year disease specific survival (DSS). A significantly 
decreased DSS is observed in tumours which exhibit high levels of FGF19 
expression, the effect of which is amplified by old age, lymph node involvement and 
negative ER status. Thus, higher levels of FGF19 expression appears to be associated 
with a poor prognositic outcome and as such may be a useful biomarker in breast 
cancer patients. In addition to its role in breast cancer, FGF19 has also been shown to 
play a role in the development of hepatocellular carcinomas in FGF19 transgenic 
murine models [80], as well as the development of prostate carcinomas [81]. 
 
 
Impaired termination of FGF-FGFR signalling 
Impaired termination of FGF-FGFR signalling can lead to increased levels of FGFRs 
on the cell surface and thus contribute to tumorigenesis. There are several different 
mechanisms through which FGFR activity may be terminated. The first occurs via 
dephosphorylation/phosphorylation events at the cell surface [82]. Signalling may be 
controlled through an ERK-mediated negative feedback loop, operating via the 
docking protein, FRS2α. Activated ERK1/2 may phosphorylate FRS2α on numerous 
threonine and serine residues, which in contrast to phosphorylated tyrosine residues, 
inhibit the docking of downstream signalling proteins such as Grb2 [82].  
 
Alternatively, signalling may be ceased through the activation of MAPK phosphatases 
[83] and via Sprouty [84] and Sef proteins [85], which have been identified as 
negative regulators of the FGFR signal transduction pathway. The loss of function of 
the aforementioned proteins can result in aberrant signalling and thus contribute to 
oncogenesis.  
 
RTK signalling may also be down regulated via ligand stimulated endocytosis and 
subsequent intracellular degradation of both the receptor and ligand in lysosomes 
[86], a process that is, in part, facilitated by Cbl-mediated monoubiquitination [87]. 
Interestingly, different FGFR isoforms have distinct susceptibilities for ubiquitination 
[88]. FGFR1 is more easily ubiquitinated than FGFR4, which has scarcely any 
ubiquitination sites and is degraded much more slowly than FGFR1-3 [89]. 
Disruptions to any step in the endocytic pathway may lead to defective internalization 
and hence, prolonged signalling [90]. Mutations in Cbl ubiquitin ligase have been 
identified in acute myeloid leukaemia (AML), resulting in accumulation of the RTK 
FLT3 [90].  
 
Mutations in the receptor itself can also contribute to defective degradation and 
sustained signalling. It has been shown that the FGFR3 G380R mutation, identified in 
bladder, prostate and testicular cancers, as well as achrondroplasia avoids efficient 
degradation by escaping into a recycling pathway, thus prolonging signalling [91]. 
Furthermore, alternative splicing of the receptor has been implicated in 
carcinogenesis. As mentioned above, C-terminal truncation of FGFR2 results in 
impaired internalization and constitutive receptor activation [56].  
 
 
Therapeutic Approaches 
As described above, FGF/FGFR signalling is frequently deregulated in a variety of 
human cancers. As such, several targeted therapies are being investigated to disrupt 
FGF/FGFR activity. These include: tyrosine kinase inhibitors, FGF-ligand traps and 
monoclonal antibodies (Table 2). 
 
 
Tyrosine Kinase Inhibitors 
FGFR tyrosine kinase inhibitors (TKIs) can be classified into two distinct groups, 
multi-target or non-selective FGFR TKIs and selective FGFR TKIs. The former 
includes FGFRs and their panel of targets as well as a number of other growth factor 
receptors, including vascular endothelial growth factor receptors (VEGFRs) and 
platelet derived growth factor receptors (PDGFRs), due to the high structural 
similarity of their tyrosine kinase domains [92]. Multi-target FGFR inhibitors are 
beneficial in that they may target numerous tumorigenic growth factors at the same 
time, however these TKIs are often less potent against FGFRs and exhibit multiple 
side effects.  In contrast, the latter encompasses compounds that are highly potent, 
FGFR specific TKIs, which are selective for FGFRs above other growth factor 
receptors [92]. Small-molecule TKIs operate by targeting the ATP binding site of the 
intracellular tyrosine kinase domain of the receptor, thus inhibiting the activity of the 
receptor [93]. There are currently several pharmaceutical companies involved in the 
development of both multi-target and selective FGFR TKIs. Interestingly a recent 
report on the development of two next-generation covalent FGFR irreversible 
inhibitors, namely FGFR inhibitors 2 (FIIN-2) and 3 (FIIN-3) has demonstrated the 
possibility of designing inhibitors that co-target two mutant kinases (B). FIIN-2 and 
FIIN-3 potently inhibit the proliferation of cells dependent upon the gatekeeper 
mutants of FGFR1 or FGFR2, which confer resistance to first-generation FGFR 
inhibitors such as NVP-BGJ398 and AZD4547. FIIN-3 inhibits both the EGFR and 
FGFR covalently by targeting two distinct cysteine residues (FGFR4 V550L and 
EGFR L858R). These FGFR inhibitors will enable further preclinical validation and 
will inspire the development of next-generation FGFR-directed therapy (B). 
 
 
Multi-target FGFR TKIs 
TK1258 (Dovitinib), by Novartis, is an oral, multi-target tyrosine kinase inhibitor that 
shows in vitro IC50 values of approximately 10nmol/L for FGFR1-3, VEGFR1-3 and 
PDGFR. Phase I studies have suggested that Dovitinib has a tolerable safety profile 
and effectively targets FGFRs at therapeutic doses. In vivo results indicate that 
Dovitinib prevents tumour growth at 30mg/kg dose and results in tumour regression 
at 50mg/kg dose. The efficacy of Dovitinib as an anti-tumour drug was evaluated in a 
phase II trial involving 79 female patients with HER2-negative metastatic breast 
cancer, on the basis of FGFR1 amplification and hormone receptor (HR) status [94]. 
FGFR1
+
/HR
- 
patients were disregarded due to their low incidence. The results 
obtained in this study showed limited activity in FGFR
+
/HR
+ 
(n=20)
 
as no complete 
responses or confirmed partial responses were observed. However, three patients 
demonstrated an initial unconfirmed response, while two additional patients had 
stable disease of ≥ 24 weeks. Only 1 patient in the FGFR-/HR+ (n=34) group and 2 
patients in the FGFR
-
/HR
-
 (n=22) group demonstrated partial response and were 
excluded from further studies. Subsequent studies of the FGFR
+
/HR
+
 group illustrated 
that Dovitinib is more potent in tumours with higher levels of FGFR1 amplification. 
Furthermore, it was shown that plasma FGF23 levels increased by approximately 
100% during the first cycle of treatment and that this was sustained, indicating 
FGFR1 inhibition. In another example, a phase III trial evaluating the efficacy of 
Dovitinib versus Sorafenib in the treatment of renal cell carcinoma in patients who 
have progressed on VEGF-target therapies has recently been completed 
(clinicaltrials.gov; NCT01223027). Results indicate that no significant differences in 
efficacy outcomes were observed in those who received Dovitinib and those who 
received Sorafenib [95]. An 11-month median overall survival period was noted in 
both groups, illustrating the need for further research, in order to develop a drug more 
efficient in the treatment of RCC. 
 
AP24534 (Ponatinib) is an orally available multi-kinase inhibitor that potently inhibits 
both wild type and mutant forms of BCR-ABL. Ponatinib demonstrates potent in vitro 
biochemical activity, with IC50 values less than 20nmol/L against approximately 40 
different tyrosine kinases including FGFR1-4 [96]. indicating potential for Ponatinib 
as a pan-FGFR inhibitor. Gozgit et al. investigated the anti-FGFR activity of 
Ponatinib across 14 different cancer cell lines, in addition to in vivo xenograft models 
[97]. They demonstrated that it had the potential to inhibit both in vitro and in vivo 
cellular proliferation and signalling. Furthermore, phase I studies in patients with 
chronic myelogenous leukaemia (CML) and BCR-ABL positive acute lymphoblastic 
leukaemia (ALL) have revealed clinical anti-tumour activity in patients resistant to 
approved second generation TKIs, Dasatinib and Nilotinib (Clinicaltrials.gov: 
NCT01207440). A phase II study is currently underway in order to determine the 
efficacy of Ponatinib in patients with CML or ALL. 
 
BIBF1120 (Nintedanib) by Boehringer-Ingelheim is a novel, multi-kinase inhibitor of 
VEGFR1-3, FGFR1-3 and PDGFR in addition to inhibiting members of the Src 
family, which are involved in tumorigenesis [98]. A phase I does escalating trial of 
once and twice daily, orally administered BIBF1120 studied 61 patients with 
advanced, nonresectable solid tumours [99]. Efficacy data showed promising results; 
complete response was observed in one patient with renal cell carcinoma and partial 
responses were observed in a patient with renal cell cancer and another with 
hepatocellular cancer. In general, drug related adverse events were mild and most 
frequently included nausea and diarrhea. These results indicate the need for further 
investigation of BIBF1120 as a targeted therapy.  
 
 
FGFR specific TKIs 
FGFR specific TKIs are selective for FGFRs above other tyrosine kinases and have 
shown promising results. PD1730174 is an example of an FGFR specific TKI that is 
frequently used in the lab and has shown potent anti-tumour activity in both in vitro 
and in vivo models with FGFR alterations. However despite promising results in the 
lab, PD1730174 has toxicity issues and is unlikely to be used in the clinic [100]. 
Several other new drugs are currently in the development process. AZD4547, a 
pyrazoloamide derivative, is an orally available, novel and selective FGFR inhibitor, 
with in vitro IC50 values of 0.2, 2.5 and 1.8 nmol/L against FGFR1, FGFR2 and 
FGFR3 respectively [101]. AZD4547 exhibits some activity against VEGFR, 
however this is approximately 120 fold lower than activity against FGFR1. Gavine et 
al. investigated the efficacy of AZD4547 as an FGFR inhibitor using various tumour 
cell lines, representing both wild type and mutant FGFR proteins [101]. They 
demonstrated that AZD4547 inhibited downstream FGFR signalling and supressed 
tumour cell growth in cell lines that exhibited atypical FGFR expression. Moreover, 
in vivo experiments using xenograft models illustrated that oral administration of 
AZD4547 was well tolerated and resulted in dose-dependant anti-tumour activity. 
There are numerous clinical trials underway studying AZD4547 and its effects. A 
phase I, dose-escalating trial is on going to investigate the safety and tolerability of 
AZD4547 when administered orally to patients with advanced solid tumours 
(clinicaltrials.gov; NCT00979134). A phase II trial is currently recruiting participants 
to assess the safety and efficacy of AZD4547 in combination with nonsteroidal 
aromatase inhibitors, anastrozole or letrozole in ER
+
 breast cancer (clinicaltrials.gov; 
NCT01791985). The study will be carried out in two phases, first to find a suitable 
dose of AZD4547, which may be used in conjunction with nonsteroidal inhibitors. 
This will be followed by a comparison of this new treatment plan against the current 
standard treatment using a steroidal aromatase inhibitor. Furthermore, AZD4547 has 
recently been included in a phase II/III trial aimed at estabilishing a method for 
genomic screening of NSCLC and squamous cell lung cancer populations 
(clinicaltrials.gov;NCT02154490). Genomic profiling will match patients to a specific 
treatment designed to target the genomic aberration that is driving tumour progression 
[102]. Each participant in the trial will be assigned to a sub-study within the trial, as 
determined by the type of biomarkers present in their tumour. AZD4547 will be 
administered orally to those with FGFR mutated tumours. 50% of patients with 
FGFR1-3
 
mutated tumours, will be given AZD4547 while the remaining 50% will be 
given the chemotherapeutic docetaxel.  
 
BGJ398 is a selective pan-FGFR inhibitor, showing greatest activity against FGFR1-
3, with IC50 values <10 nmol/L [103]. BGJ398 also exhibits some activity against 
VEGFR, however this is approximately 70-100 fold lower than activity as compared 
with FGFR1-3. The efficacy and safety of BGJ398 as an anti-cancer drug is currently 
being evaluated in a phase I dose-escalation study involving patients with advanced 
solid tumours with alterations of FGFR1, 2 and/or 3 (clinicaltrials.gov; 
NCT01004224). Preliminary results from the first 26 patients are available and are 
promising; a 33% reduction in target lesions after 8 weeks of treatment was observed 
in an FGFR1 amplified lung cancer patient, providing early evidence that inhibition of 
FGFRs by TKIs may be an effective treatment in cancer patients [104]. In general 
drug related adverse events were grade 1 or grade 2. The most frequent adverse events 
observed included gastrointestinal events and fatigue. However, as is the case with 
most selective anti-FGFR TKIs, dose dependant hyperphospahatemia was observed 
due to obstruction of FGF23 signalling. This could be controlled with use of 
phosphate binders and diuretics.  
JNJ‐42756493 is a selective highly potent pan-FGFR inhibitor that was designed 
using structure based drug approach coupled to a fragment based approach. Currently 
this drug is being tested in several studies including (i) to evaluate its safety, 
pharmacokinetics, and pharmacodynamics in adults with advanced or refractory solid 
tumors or lymphoma (NCT 01703481) (E) and (ii) a phase 1/2a study to evaluate the 
safety, pharmacokinetics, and pharmacodynamics in subjects with advanced 
hepatocellular carcinoma with fibroblast growth factor (FGF) 19 amplification 
(NCT02421185) as well as a Phase 2, in subjects with metastatic or surgically 
unresectable urothelial cancer with FGFR genomic alterations (NCT 02365597). 
 
TAS‐120 is a second generation, highly potent irreversible inhibitor of all FGFRs 
with good selectivity versus other 276 kinases. TAS‐120 is effective in tumors 
harboring FGFR mutations, resistant to ATP competitive inhibitors (F, G).  
 
INCB054828 is a potent inhibitor of FGFR1, FGFR2, and FGFR3 that has selective 
pharmacological activity against cancer cells with FGFR alterations. Currently a 
Phase I study is on-going to evaluate the safety, tolerability, and pharmacological 
activity of INCB054828 in subjects with advanced malignancies (NCT02393248) 
(H). 
 
 
 
FGF ligand traps 
FGF/FGFR activity may also be inhibited by use of FGF ligand traps, which act to 
sequester FGF ligands, thus preventing them from binding to and activating their 
cognate receptors. FP-1039 (also known as GSK3052230), developed by Five Prime 
Therapeutics is an example of an FGF ligand trap consisting of the extracellular 
domain of human FGFR1 IIIc splice variant, linked to the crystallisation fragment 
(Fc) region of human immunoglobulin G. FP-1039 binds firmly to all of the 
mitogenic FGF ligands but does not bind to the hormonal FGFs, as these ligands 
require a co-receptor in order for binding and signalling to occur [105]. Preclinical 
studies performed in both in vitro and in vivo models have confirmed anti-angiogenic 
and anti-tumorigenic activity of FP-1039. A phase I dose-escalating trial evaluating 
the safety and tolerability of FP-1039 as a novel cancer therapeutic in patients with 
metastatic, advanced solid tumours has recently been completed (Clinicaltrials.gov; 
NCT00687505). Phase Ia results indicate that treatment with FP-1039 in patients with 
solid tumours did not result in side effects such as hyperphospahatemia, as observed 
in clinical trials with FGFR specific TKIs. Hence it is anticipated that patients will 
better tolerate FP-1039. A phase Ib is currently enrolling patients with squamous 
NSCLC with FGFR1 amplification (Clinicaltrials.gov; NCT01868022). In another 
example, the aim of a recent phase II trial was to test the activity and safety of FP-
1039 in patients with advanced and/or recurrent endometrial cancer with specific 
FGFR2 mutations (Clinicaltrials.gov; NCT01244438). However this trial was 
subsequently withdrawn from study prior to the enrolment phase, as it was deemed 
not to be feasible. After the screening of 70 patients, a suitable patient had yet to be 
found and the original expectation that at least 5% of patients screened would qualify 
for the study was not met.  
 
 
 
Monoclonal Antibodies 
Another approach for inhibiting FGF/FGFR activity is through use of monoclonal 
antibodies, which are not only highly specific for a particular FGF ligand or FGFR 
isoform, but also minimise the common side effects associated with inhibition of 
multiple FGFR isoforms. Several therapeutic monoclonal antibodies targeting 
FGF/FGFR signalling have shown anti-tumour activity in both cancer cell lines and 
murine models. GP369 is an example of an FGFR2-IIIb-specific monoclonal 
antibody, which targets the extracellular ligand binding domain of the receptor and 
exhibited potent inhibitory activity in several FGFR2-mutated human cancer cell lines 
as well as significantly inhibiting the in vivo growth of FGFR2-amplified human 
breast and gastric cancer xenografts [106]. Moreover, R3Mab, a monoclonal antibody 
that acts specifically on FGFR3 has shown inhibitory activity on tumour growth in 
various bladder cancer cell lines and murine xenografts [107, 108], in addition to 
exerting potent anti-tumour activity against (t4;14)-positive MM murine xenografts 
[109].  However, despite the fact that several monoclonal antibodies targeting 
FGF/FGFR signalling have shown potent anti-tumour activity in both in vitro and in 
vivo models, very few have progressed to clinical trial. MFGR1877S, developed by 
Genentech Inc. is an example of one of the few FGFR targeted monoclonal antibodies 
in clinical development. This anti-FGFR3 antibody has been evaluated in two 
separate phase I trials; in t(4;14) MM patients (clinicaltrials.gov; NCT01122875) as 
well as in patients with advanced solid tumours (clinicaltrials.gov; NCT01363024). 
Results of these trials have yet to be published. 
 
 
 
 
 
 
 
 
 
 
 
Drug Company Target Clinical Development 
Tyrosine Kinase Inhibitors 
AZD4547 AstraZeneca FGFR1-3 Phase II (breast cancer) - (NCT01791985) 
Phase II/III (squamous cell lung cancer) -  
(NCT02154490) 
BGJ398 Novartis FGFR1-3 Phase I (solid tumours) -  (NCT01004224) 
Brivanib alaninate BMS VEGFR, FGFR Phase II (endometrial cancer) – (NCT00888173) 
 
Cediranib AstraZeneca VEGFR, 
FGFR1,2 
 
Dovitinib 
 
Novartis FGFR1-3, 
VEGFR1-3, 
PDGFR 
Phase III (RCC) - (NCT01223027) 
Phase II (breast cancer) – NCT00958971) 
Lenvatinib Eisai VEGFR, FGFR Phase II (NSCLC) – (NCT01529112) 
Phase I/II (solid tumors) – (NCT02432274) 
Lucitanib Servier VEGFR1-3, 
FGFR1,2 
PhaseI/II (solid tumours) – (NCT01283945) 
LY2874455 Eli Lilly FGFR1-4 Phase I (solid tumours) -  (NCT01212107) 
Nintedanib Boehringer 
Ingelheim 
FGFR1-3, 
VEGFR1-3, 
PDGFR, Src 
family 
Phase I (solid tumours) – (NCT01951846) 
Ponatinib Ariad FGFR1-4, 
VEGFR2 
Phase II (ALL, CML) - (NCT01207440) 
Sulfatinib Hutchison 
Medipharma 
VEGFR1-3, 
FGFR1 
Phase I (solid tumours) – (NCT02133157) 
PD173074 Pfizer Pan-FGFR, 
VEGFR2 
 
JNJ‐42756493 Janssen R&D, 
LLC 
 
Pan-FGFR Phase I (solid tumours or lymphoma) NCT 
01703481 
Phase I/IIa (advanced hepatocellular 
carcinoma) NCT02421185 
Phase II (Urothelial Cancer)– (NCT02365597) 
TAS-120 
Taiho 
Pharmaceutical 
Co., Ltd 
 Phase I (solid tumours or multiple myeloma) 
(NCT02052778) 
INCB054828 
Incyte 
Corporation 
FGFR1-3, Phase I (advanced malignancies) 
(NCT02393248) 
Debio 1347-101 
 
Debiopharm 
International SA 
FGFR1-3 Phase I (Advanced solid tumours with FGFR 
Alterations) (NCT01948297) 
FGF Ligand Traps 
FP-1039 
 
Five Prime 
Therapeutics 
Mitogenic FGFs Phase I (solid tumours) - (NCT00687505) 
Phase I (NSCLC) - (NCT01868022) 
Phase II (endometrial cancer) - (NCT01244438) 
Monoclonal Antibodies 
MFGR1887S Genentech 
Inc. 
FGFR3 Phase I (solid tumours) - (NCT01363024) 
Phase I (MM) - (NCT01122875) 
Table 2: FGF/FGFR targeting anti-cancer drugs and their current clinical development 
standing. 
 
In addition to the various TKIs that target FGFRs that are currently in 
development, several multi-target TKIs, which target FGFRs amonst a number of 
other tyrosine kinases, have been approved for the treatment of a variety of 
different cancer types, as illustrated in Table 3. 
 
 
Name Targets  
Pazopanib 
 
FLT1, FLT3, FLT4, KDR, 
KIT, PDGFRA, PDGFRB, 
RET, TEK, FGFR1, FGFR3, 
FGFR2, FGFR2_N549H 
 
Approved for advanced soft 
tissue sarcoma 
Approved for advanced renal 
cell carcinoma 
 
Regorafenib 
 
BRAF, KDR, KIT, PDGFRA, 
PDGFRB, RAF1, RET, FLT1, 
FLT3, FGFR1, FGFR2, PTK5, 
SAPK2, TIE2, ABL, NTRK1, 
EPHA2 
 
Approved for advanced 
gastrointestinal stromal tumors 
(GIST) 
Approved for previously 
treated metastatic colorectal 
cancer 
 
Sorafenib 
 
ABL1, ARAF, BRAF, 
FGFR1, KIT, PDGFRA, 
PDGFRB, RAF1, RET, FLT1, 
FLT3, KDR, FLT4, FGFR2, 
FGFR2_N549H 
 
Approved for thyroid cancer 
Approved for liver cancer 
Approved for kidney cancer 
 
 
Sunitinib 
 
FLT1, KDR, FLT3, FLT4, 
PDGFRA, PDGFRB, KIT, 
RET, ZNF198-FGFR1, 
CSF1R, FGFR1, FGFR2, 
FGFR2_N549H 
 
Approved for pancreatic 
neuroendocrine tumors 
Approved for kidney cancer 
Approved for gastrointestinal 
stromal tumor. 
 
Table 3: Approved multi-target TKIs, their targets and the tumour types for which they are 
approved to treat. 
 
 
Resistance to FGFR inhibitors 
Acquired mechanisms of  resistance,  limits the overall efficacy of tyrosine kinase 
inhibitors and monoclonal antibodies [110]. EGFR activation has recently been 
identified by Herrera-Abreu et al. as a mechanism of resistance in FGFR3-mutant 
bladder cancers [6]. Two distinct mechanistic groups have been described; FGFR3-
dependant cell lines, in which FGFR inhibition results in the subsequent upregulation 
of EGFR signalling through release from a negative feedback loop and EGFR-
dependant cell lines, in which EGFR dominates downstream signalling by repression 
of FGFR3 expression, despite the presence of an FGFR3-activating mutation. Both in 
vitro and in vivo targeting of either group with a combination of PD173074 and an 
EGFR inhibitor, Gefitinib or Cetuximab, resulted in increased efficacy compared with 
either treatment given alone. Treatment with just PD173074 resulted in tumour stasis, 
in contrast to combination therapy which resulted in a significant reduction in tumour 
burden. Furthermore, tumour growth rapidly recommenced upon cessation of 
treatment with PD173074 alone, differing from combination-treated mice which 
exhibited sustained tumour control. The theory that activation of members of the 
EGFR family could serve as a mechanism of resistance to inhibitors targeting a 
mutant oncogene has also been shown to occur in triple negative breast cancer [111]. 
Interestingly, FGFR activation has been identified as a mechanism of acquired 
resistance to targeted therapies targeting members of the EGFR family in NSCLC 
[112-114], illustrating the potential for co-targeting strategies in the future. 
 
HGF, the only known ligand of c-MET has also recently been identified by Harbinski 
et al. as a strong rescuer from FGFR inhibition [115]. Co-activation of c-MET and 
FGFR has been observed in several cancer cell lines. Inhibition has been investigated 
using MET inhibitors, FGFR inhibitors as well as a combination of both. MET 
inhibition alone had no effect, while FGFR inhibition resulted in a partial suprresion 
of cell growth. However, combined inhibition of both MET and FGFR demonstrated 
the most promising effect, resulting in a more profound supression of tumour cell 
growth than either inhibitor alone. Furthermore, similar anti-tumour efficacy was 
observed in vivo when a combinatorial approach was used. 
 
 
Conclusion 
Deregulation of the FGF/FGFR signalling axis is observed in a wide variety of human 
carcinomas. Targeting of both FGFs and FGFRs in cancer is a relatively new field of 
research. However, the results of numerous preclinical and clinical trials, testing 
drugs that selectively target the FGF/FGFR axis in patients with FGFR deregulated 
tumours, have been promising. The success of FGFR targeted therapies is dependent 
on in-depth mutation profiling of tumours and the development of a more 
personalised treatment plan, treating individual patients with the correct drug for the 
correct target. Stratifying patients prior to treatment may alleviate some of the 
toxicities that have been challenging selective FGFR inhibitors to date. The 
development of dual kinase targeting inhibitors, such as FIIN-3, have important 
implications for the design of covalent FGFR inhibitors that can overcome clinical 
resistance and that may significantly benefit countless patients in the future.  
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